The present application relates to medical systems, devices, and methods. In particular, the present application relates to the construction, use, and function of surgical incision closure devices with integrated therapeutic and/or sensor properties.
Medical devices, systems, and methods which incorporate therapeutic and/or sensory capabilities into a wound closure device are disclosed herein.
The inventors of the present application have previously disclosed inventions relating to surgical skin closure. Such skin closure appliances are described, for example, in U.S. Provisional Application Nos. 61/958,254 and 61/958,259, both filed Jul. 24, 2013, and U.S. patent application Ser. No. 14/180,524, filed Feb. 14, 2014, the contents of which are incorporated herein by reference. As described, an adhesive patch may be placed over a patient's skin at a site where it is desired to form a surgical incision. After the patch is placed, an incision is formed along an axial line extending through the middle of the patch. After it is formed, the incision can be opened to perform a desired procedure, and after the procedure is completed, the incision may be closed by drawing the inner edges of the panels together with a clip, zipper, ratchet, strap, or other closure member(s). Such surgical closure devices are meant to improve healing and reduce scarring from the incision.
Topical sensors, including those measuring motion, acceleration, stress/strain, temperature, pressure, oxygen saturation and tension, CO2 tension, moisture and other parameters, are well known in the art and the medical device market. However, incorporation of such sensors and functionality into wound closure devices and/or use in conjunction with post-operative physical therapy is yet to be available in the marketplace. In addition, delivery of therapeutic capabilities, including delivery of heat, light (including infrared, visible and ultraviolet), electrical signals, motion (e.g., vibration), and pressure, are well known in the art and the medical device market. However, incorporation of such properties into a wound closure device and/or use in conjunction with post-operative physical therapy is yet to be available in the marketplace. Aspects of the present disclosure provide wound or incision closure appliances and methods of use which incorporate at least some of the aforementioned capabilities.
Aspects of the present disclosure provide wound or incision closure apparatuses comprising a first panel for placement laterally adjacent a first lateral side of a wound or incision, a second panel for placement laterally adjacent a second lateral side of the wound or incision, and a sensory or therapeutic element disposed adjacent or integrated into one or more of the first or second panels. The first panel may comprise a first bottom adhesive layer, a first medial substrate layer, and a first upper load distribution layer. Similarly, the second panel may comprise a second bottom adhesive layer, a second medial substrate layer, and a second upper load distribution layer connectable to the first upper load distribution layer, for example through one or more straps and strap ratchets. The different layers of the panels may be constructed of a variety of materials as described further below.
The sensory or therapeutic element may be disposed adjacent or integrated into one or more of the first bottom adhesive layer, the second bottom adhesive layer, the first medial substrate layer, the second medial substrate layer, the first upper load distribution layer, or the second upper load distribution layer. The sensory or therapeutic element may be disposed within a pocket between two or more of the layers of one or more of the first or second panels. The first or second panels may have an access traversing one or more of the layers to allow access to the pocket.
The sensory or therapeutic element may be configured to be in communication, such as wireless communication (e.g., Bluetooth, Bluetooth LE, WiFi, IR signal(s), and the like) with a receiving device external of the wound or incision closure apparatus. The receiving device may comprise a workstation, a personal computer, a laptop computer, a tablet computer, a smartphone, a wearable computer, a dedicated receiver, or the like.
The sensory or therapeutic element may comprise one or more of a thermometer, a motion sensor, a chemical sensor, a pressure sensor, a therapy delivery element, or other sensor. A motion sensor may, for example, comprise one or more of a strain gauge, an electromechanical sensor, an electromagnetic sensor, an accelerometer, an optical sensor, or other motion sensor. A chemical sensor may, for example, be configured to measure one or more of blood composition, transcutaneous oxygen, transcutaneous carbon dioxide, glucose levels, or pH. A therapy delivery element may, for example, comprise one or more of a light source for phototherapy, a mechanical vibration element, an ultrasound source, a drug delivery element, a heating element, a cooling element, an electrifying element, or an ultrasound source.
Aspects of the present disclosure also provide methods of treating a wound or incision. A first panel of a wound or incision closure apparatus may be adhered adjacent a first lateral side of the wound or incision. A second panel of the closure apparatus may be adhered adjacent a second lateral side of the wound or incision. The first and second panels may be drawn laterally together to draw the first and second lateral sides of the wound or incision together. A physiological parameter(s) may be sensed with a therapeutic or sensory element disposed on or within one or more of the first or second panels. The therapeutic or sensory element may sense the physiological parameter(s) intermittently (e.g., at the discretion of the user such as according to a schedule) and/or continuously (including at closely timed intervals, or once or a set number of times every one or more hours, one or more minutes, or one or more seconds). The physiological parameter(s) may comprise, for example, one or more of temperature, motion, moisture, pressure, the concentration of a physiological marker, pH, oxygen levels, carbon dioxide levels, or glucose levels, to name a few.
The method may further comprise a step of providing a therapy to patient with the therapeutic or sensory device. The therapy may comprise one or more of phototherapy, vibration therapy, ultrasound therapy, drug delivery, heat therapy, cooling therapy, or electrical therapy, to name a few.
The method may further comprise a step of transmitting the sensed physiological parameter(s) to an external receiving device. The transmission may be in real time with the sensing or detection of the physiological parameter(s) by the therapeutic or sensory device. The external receiving device may comprise one or more of a workstation, a personal computer, a laptop computer, a tablet computer, a smartphone, a wearable computer, or a dedicated receiver, to name a few.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the present disclosure are utilized, and the accompanying drawings of which:
The present disclosure relates to wound closure devices incorporating therapeutic and/or sensory capabilities and their methods of use.
Incorporation of therapeutic and/or sensory capabilities.
The adhesive layer 116 may comprise a hydrophilic adhesive material such as one or more of a hydrocolloid, a hydrogel, an acrylic polymer, or poly (ethylene glycol). Hydrocolloid adhesives may have the benefit of being very tacky and able to absorb moisture and shedding skin cells. Thus, hydrocolloid adhesives may be particularly suited for long-term wear applications (e.g., up to 14 days). The substrate layer 114 may comprise one or more of rubber, latex, urethane, polyurethane, silicone, a thermoplastic elastomer (TPE), a woven fabric, or a spun fabric. The load distribution elements 112 may be made of similar materials as the substrate layer 114. The upper layers, the substrate layer 114 and the load distribution elements 112, will typically be flexible but stiff enough to securely close tissue and minimize disruption of the incision and surrounding tissue. The bottom layer 116 will typically be flexible and more elastic than the upper layers 114, 116 to maintain adhesion, minimize blistering, and otherwise reduce irritation.
One or more of the components of the incision closure appliances or incision closure appliance assemblies disclosed herein may be comprised of, be coated with, or otherwise incorporate one or more of an antifungal, antibacterial, antimicrobial, antiseptic, or medicated material. For example, such materials may be incorporated into the hydrocolloid adhesive layer, as another layer or coating between the skin and the adhesive layer (covering at least a portion of the adhesive layer), incorporated into the base assembly cover or at least its adhesive layer, etc. One or more wells, grooves, openings, pores, or similar structures may be provided on the device or apparatus components to facilitate such incorporation. In many embodiments, such materials may comprise one or more of silver, iodide, zinc, chlorine, copper, or natural materials such as tea tree oil as the active agent. Examples of such antifungal, antibacterial, antimicrobial, antiseptic, or medicated materials include, but are not limited to, the Acticoat™ family of materials available from Smith & Nephew plc of the U.K., the Acticoat® Moisture Control family of materials available from Smith & Nephew plc of the U.K., the Contreet® Foam family of materials available from Coloplast A/S of Denmark, the UrgoCell® Silver family of materials available from Urgo Limited of the U.K. (a subsidiary of Laboratoires URGO of France), the Contreet® Hydrocolloid family of materials available from Smith & Nephew plc of the U.K., the Aquacel® Ag family of materials available from ConvaTec Inc. of Skillman, N.J., the Silvercel® family of materials available from Kinetic Concepts, Inc. of San Antonio, Tex., Actisorb® Silver 220 available from Kinetic Concepts, Inc. of San Antonio, Tex., the Urgotul® SSD family of materials available from Urgo Limited of the U.K. (a subsidiary of Laboratoires URGO of France), the Inadine® family of materials available from Kinetic Concepts, Inc. of San Antonio, Tex., the Iodoflex® family of materials available from Smith & Nephew plc of the U.K., the Sorbsan Silver™ family of materials available from Aspen Medical Europe Ltd. of the U.K., the Polymem Silver® family of materials available from Ferris Mfg. Corp. of Burr Ridge, Ill., the Promogram™ family of materials available from Kinetic Concepts, Inc. of San Antonio, Tex., the Promogram Prisma™ family of materials available from Kinetic Concepts, Inc. of San Antonio, Tex., and the Arglaes® family of materials available from Medline Industries, Inc. of Mundelein, Ill. Components of the closure devices described in commonly owned U.S. Pat. Nos. 8,313,508, 8,323,313, and 8,439,945; U.S. Patent Publication No. 2013/0066365; and PCT application nos. US 2010/000430, US 2011/139912, US 2011/40213, US 2011/34649, and US 2013/067024 may also be comprised of, be coated with, or otherwise incorporate one or more of an antifungal, antibacterial, antimicrobial, antiseptic, or medicated material, including but not limited to one or more of the materials listed above.
In many embodiments, topical medicinal agents are incorporated directly into the wound closure appliances described herein. Because a wound closure device is often applied in close proximity to a wound or incision in need of medicinal protection, the incorporation of such medicines directly into the closure device may be beneficial. In wounds at risk of infection, incorporation of anti-microbial agents may be beneficial, for example. Anti-microbial agents may include antibiotic medicines as well as antiseptic metal ions and associated compounds which may include silver, iodine, copper, and chlorine, or natural materials such as tea tree oil. In wounds prone to fungus, medicinal agents such as zinc may be warranted, for example. Combinations of any of these agents may also be of benefit and thus may be incorporated into wound closure appliances.
Topical medicinal agents may be incorporated into the closure devices in a way to give the closure devices the ability to wick exudate away from the wound (e.g., to direct unwanted organisms away from the wound and/or prevent skin maceration), while keeping the wound sufficiently hydrated for improved healing.
One or more therapeutic or sensory element 130 may be embedded into the material of the panel 100 as shown in
The therapeutic or sensory element(s) 130 may be embedded into a pocket created within one or more of the panels 102 or 104 as shown in
The therapeutic or sensory element(s) 130 may be attached to the top or upper surfaces of the device 100 as shown in
The therapeutic or sensory element(s) 130 may be attached or embedded on a removable or attachable portion 140 of device 100 as shown in
Manners of Activation and/or Sensing.
The therapeutic or sensory element(s) 130 can be activated or can transmit sensed information in at least the following manners.
The therapeutic or sensory element(s) 130 may be in direct contact with a receiving element. The receiving element may comprise a computing device (e.g., a workstation, a personal computer, a tablet computer, a smartphone, a wearable computer, and the like) or dedicated diagnostic device. The connection may be achieved through the connection of electrical wires to the wound closure device 100, either in a permanent (e.g., “hard-wired”) or releasable (via connector) manner. Similarly, heat or cooling by way of a mechanical “plumbing” (e.g., fluid filled tubes) connection, either permanent or releasable, may be employed. For either electrical or mechanical construction, wires or tubes may be routed over, under, or within (embedded, laminated) the closure device 100 using elements such as adhesives, laminates, ties, clips, etc. Arrangement of the connecting elements in a serpentine or other similar pattern may be employed to provide mechanical compliance with the device 100.
The therapeutic or sensory element(s) 130 may be connected with the receiving element wirelessly. A wireless transmitter and/or receiver may be integrated into the closure device 100 to receive and/or send signals with respect to the therapeutic or sensor element(s) 130. This transmitter and/or receiver could, for example, include a battery-operated, low-power Bluetooth or other wireless electrical transmission elements to send/receive to another receiving device such as those described above.
The wound closure device 100 may be a standalone device incorporating activation, sensing, and/or display capabilities for the therapeutic or sensory element(s) 130. The wound closure device 100 may also contain the necessary electrical or mechanical elements to provide therapy or record sensor data. For example, the wound closure device 100 may include a battery-powered data recorder that can be downloaded to another receiving device at planned or random intervals. This connection with the receiving device may also take the form of a self-contained internal feedback loop, where sensor data is monitored and an electrical or mechanical element is activated when sensor data exceeds a pre-set threshold. An example may be a vibration stimulus in the wound closure device 100 notifying the patient when a sensed parameter, such as motion (relative or absolute), temperature or pressure, exceeds a pre-set threshold. Another example may be an optical or magnetic sensor to detect proximity between one or more therapeutic or sensory elements 130.
Sensors.
The following section provides examples of sensors which the therapeutic or sensory element 130 may comprise. Sensors 130 of one type may be integrated into the wound closure device 100, or several different sensors and/or therapeutic elements 130 may be embedded into a single wound closure device 100.
The therapeutic or sensory element(s) 130 may comprise a skin temperature sensing element. The wound closure device 100 may measure temperature using an infrared sensor or using any other way of directly or indirectly measuring the temperature. The temperature sensing element 130 and/or the wound closure device 100 including such an element may be isolated from the surrounding ambient to prevent false reading (e.g., be covered from the outside by an isolating layer or the like). The temperature sensor 130 may record the temperature intermittently or continuously. The temperature sensing wound closure device 100 may be set to send an alarm with an ability to set the temperature required to set off the alarm. Since infection is often associated with hyperemia and increased temperature, the temperature sensing wound closure device 100 may serve as a way for early detection of infection. The alarm could be in many ways—audible, visible LED, vibration, Bluetooth connection to a smartphone or other types of computing devices, etc.
Alternatively or in combination, the therapeutic or sensory element(s) 130 may comprise a mechanical motion sensor. Mechanical motion may be sensed via integrated sensors in the form of strain gauges, electromechanical sensors, electromagnetic sensors, accelerometers, or optical sensors. One or more of the sensors 130 may be used to define changes in position relative to itself and/or other sensors 130 in 3D space, or may simply record binary proximity triggers. The sensor 130 may detect maximum distance or range achieved, or may measure frequency and range of motion over time (e.g., number of times a patient flexes the knee each day during the first three days post-surgery.) Sensor data may be collected via integrated data recording means, or transmitted by wire or wirelessly (e.g., Bluetooth) to an external device such as a dedicated data logger, smartphone application, or other medical device where the data can be presented (e.g., data table, data summary, or graphic form), can be used to trigger an alarm, or can be transmitted to a clinician remotely for patient monitoring without requiring the patient's return to a clinic.
The detection of mechanical motion can alert a practitioner of the range or frequency of mobility of a patient's joint after surgery, for example to monitor compliance with recommended therapeutic regimen after joint surgery or replacement. For example, if a patient is instructed to bend a joint over a certain range and at a certain frequency, this device 100 may alert the practitioner if a patient does not comply with this regimen so that corrective action may be taken. Alternatively or in combination, visual indicators (e.g., via color change) may be utilized to indicate amount or degree of motion. An example would be to detect and indicate maximum range of motion of a joint achieved during successive exercises, to inform the patient when to change or add elements to his/her therapeutic regimen, without requiring the monitoring and input by a clinician. The providing of such indications may reduce the overall cost of therapy by providing a self-guiding program of therapy. Another example may be an audible beep that will be heard when the joint has reached the desired amount of bending (the beeping or alarm could be programmable).
Alternatively or in combination, the therapeutic or sensory element(s) 130 may comprise sensors for determining blood or tissue chemical composition. The sensor(s) 130 may comprise transcutaneous blood composition measurement elements integrated to measure, for example, oxygen, carbon dioxide, glucose, pH, etc. for purposes of assessing wound condition. Transcutaneous oxygen or carbon dioxide measurements may serve as a good indication for tissue vitality, inflammation, infection, etc.
Alternatively or in combination, the therapeutic or sensory element(s) 130 may comprise sensors for detecting mechanical pressure. Mechanical pressure, which can indicate the degree of edema and swelling, can be measured via integrated sensor(s) 130. The degree of swelling may be used to alert a caregiver to administer swelling-reduction therapy (e.g., ice pack) or to automatically trigger or control the temperature of a cold-water circulation system integrated into the device or applied on top of the device.
Alternatively or in combination, the therapeutic or sensory element(s) 130 may comprise one or more therapeutic elements of one or more types that may be integrated into the device 100. Examples of therapeutic types of therapeutic or sensory element(s) 130 are described as follows. While certain types of therapies are described, many other types of therapies which may be delivered through one or more therapeutic or sensory element(s) are also contemplated.
The therapeutic or sensory element(s) 130 may comprise an integrated phototherapeutic delivery element configured to deliver light to the skin. The delivery of light may provide a number of different therapies.
Several different wavelengths of light may stimulate oxygen flow and the body's production of nitric oxide, which in turn may relax muscle fibers and widen blood vessels to increase blood flow to the wound.
Ultraviolet light, especially UV-C, may be delivered to the skin, either continuously or intermittently, to eradicate bacteria and prevent infection. In some embodiments, the device 100 may be battery powered and shine a light in a specific point. In some embodiments, the UV generating device may be connected to an optical fiber that will carry the light and shine it in several locations along the length of the incision. This optical fiber may include a woven or interleaved array of fibers that preferentially leak light as each fiber is bent within the array.
Infrared light may be used to affect mitochondrial enzyme (e.g., cytochrome c oxidase) function in cells that can increase ATP production and improve cellular resistance to ischemia. Infrared light may also stimulate the creation of heat shock proteins which can offer ischemic protection.
Alternatively or in combination, the therapeutic or sensory element(s) 130 deliver mechanical vibration therapy. Mechanical vibration may be integrated into the device 100 and delivered to the skin through the integration of a micro-motor or other vibrating element, and may be used as a therapeutic (e.g., pain reduction) or alerting signal. As a therapy, vibrations at a certain frequency and amplitude may saturate the sensory nerves and reduce pain at the surgical site and/or within surrounding tissues. Ultrasound vibration may be employed for deeper penetration of tissues to aid in local tissue circulation. As an alarm, vibration may be used to alert the patient of an event that requires action, such as the detection of elevated temperature or swelling.
Alternatively or in combination, the therapeutic or sensory element(s) 130 may deliver therapeutic chemicals or drugs. The device 100 may integrate an element by which a chemical agent is delivered to the skin continuously (constant concentration or tapered over time), intermittently, event-driven (such as when the skin exceeds a certain temperature), or upon demand (such as by pressing a button or feature on the device). The chemical agent may be embedded into the device materials, or may be stored in a separate but connected reservoir. Delivery may be passive or active, such as via iontophoretic or electromotive drug administration (EMDA) to deliver a medicine or other chemical through the skin, via transdermal micro needle array, via application to the skin via micro-nozzles (e.g., spray), or high pressure micro bursts of fluid capable of local tissue disruption and agent delivery.
Alternatively or in combination, the therapeutic or sensory element(s) 130 may deliver heat therapy. Small heating elements may be embedded into the device 100 that may be used to provide localized heat to the wound site.
Alternatively or in combination, the therapeutic or sensory element(s) 130 may deliver cooling therapy. The wound site may be cooled through the introduction of cooled air or water to the skin. The cooling element(s) may be integrated into the device 100 in the form of embedded channels to carry the cooling medium at or near the skin where it absorbs heat from the skin (effectively cooling the skin) and is circulated back to a cooling/pump system. Cooling can reduce the sensation of pain and can reduce swelling at the wound site.
Alternatively or in combination, the therapeutic or sensory element(s) 130 may deliver electrical signal. The application of electrical signals, for example weak current, can be used to minimize proliferation of bacteria at the wound site and can be used to promote healing. Higher radiofrequency current could also be employed for local coagulation of blood within tissues of patients prone to bleeding complications (e.g., on Heparin, Warfarin or Plavix).
Alternatively or in combination, the therapeutic or sensory element(s) 130 may ultrasound as a therapy.
Although the above steps show the method 1300 of treating a patient in accordance with many embodiments, a person of ordinary skill in the art will recognize many variations based on the teaching described above. The steps may be completed in a different order. Steps may be added or deleted. Some of the steps may comprise sub-steps. Many of the steps may be repeated as often as beneficial to the treatment.
One or more of the steps of the method 1300 may be performed with circuitry of the device 100 and/or the therapeutic or sensory element(s) 130 as described herein. The circuitry may be programmed to provide one or more of the steps of the method 1300, and the program may comprise program instructions stored on a computer readable memory or programmed steps of the logic circuitry such as a programmable array logic or a field programmable gate array.
While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the embodiments of the present disclosure described herein may be employed in practicing the inventions of the present disclosure. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application is a continuation of PCT International Application No. PCT/US2015/010188, filed Jan. 5, 2015, which claims the benefit of U.S. Provisional Application No. 61/964,477, filed Jan. 5, 2014, all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2012755 | Muth | Aug 1935 | A |
2371978 | Perham | Mar 1945 | A |
2747248 | Mercer | May 1956 | A |
3118201 | Beghetto, Jr. | Jan 1964 | A |
3487836 | Niebel et al. | Jan 1970 | A |
3516409 | Howell | Jun 1970 | A |
3698395 | Hasson | Oct 1972 | A |
3863640 | Haverstock | Feb 1975 | A |
3926193 | Hasson | Dec 1975 | A |
3933158 | Haverstock | Jan 1976 | A |
3971384 | Hasson | Jul 1976 | A |
3972328 | Chen | Aug 1976 | A |
3983878 | Kawchitch | Oct 1976 | A |
4038989 | Romero-Sierra et al. | Aug 1977 | A |
4114624 | Haverstock | Sep 1978 | A |
4210148 | Stivala | Jul 1980 | A |
4222383 | Schossow | Sep 1980 | A |
4224945 | Cohen | Sep 1980 | A |
4526173 | Sheehan | Jul 1985 | A |
4531521 | Haverstock | Jul 1985 | A |
4535772 | Sheehan | Aug 1985 | A |
4539990 | Stivala | Sep 1985 | A |
4576163 | Bliss | Mar 1986 | A |
4605005 | Sheehan | Aug 1986 | A |
4612230 | Liland et al. | Sep 1986 | A |
4676245 | Fukuda | Jun 1987 | A |
4702251 | Sheehan | Oct 1987 | A |
4780168 | Beisang et al. | Oct 1988 | A |
4871367 | Christensen et al. | Oct 1989 | A |
4881546 | Kaessmann | Nov 1989 | A |
4905694 | Will | Mar 1990 | A |
4950282 | Beisang et al. | Aug 1990 | A |
4966605 | Thieler | Oct 1990 | A |
4976726 | Haverstock | Dec 1990 | A |
5176703 | Peterson | Jan 1993 | A |
5190032 | Zacoi | Mar 1993 | A |
5259835 | Clark | Nov 1993 | A |
5306236 | Blumenfeld et al. | Apr 1994 | A |
5336219 | Krantz | Aug 1994 | A |
5377695 | An Haack | Jan 1995 | A |
5514155 | Daneshvar | May 1996 | A |
5533519 | Radke et al. | Jul 1996 | A |
5562705 | Whiteford | Oct 1996 | A |
5665108 | Galindo | Sep 1997 | A |
5725507 | Petrick | Mar 1998 | A |
5788660 | Resnik | Aug 1998 | A |
5823983 | Rosofsky | Oct 1998 | A |
5843123 | Brazeau | Dec 1998 | A |
5910125 | Cummings | Jun 1999 | A |
6007564 | Haverstock | Dec 1999 | A |
6033654 | Stedronsky et al. | Mar 2000 | A |
6074965 | Bodenschatz et al. | Jun 2000 | A |
6126615 | Allen et al. | Oct 2000 | A |
6176868 | Detour | Jan 2001 | B1 |
6194629 | Bernhard | Feb 2001 | B1 |
6629949 | Douglas | Oct 2003 | B1 |
6689100 | Connelly et al. | Feb 2004 | B2 |
6726706 | Dominguez | Apr 2004 | B2 |
7066182 | Dunshee | Jun 2006 | B1 |
7361185 | O'Malley et al. | Apr 2008 | B2 |
7455681 | Wilke et al. | Nov 2008 | B2 |
7511185 | Lebner | Mar 2009 | B2 |
7641682 | Palmaz et al. | Jan 2010 | B2 |
7645285 | Cosgrove et al. | Jan 2010 | B2 |
7799042 | Williamson, IV et al. | Sep 2010 | B2 |
8246590 | Hu et al. | Aug 2012 | B2 |
8313508 | Belson et al. | Nov 2012 | B2 |
8323313 | Belson et al. | Dec 2012 | B1 |
8439945 | Belson et al. | May 2013 | B2 |
8592640 | Zepeda et al. | Nov 2013 | B2 |
8663275 | O'Malley et al. | Mar 2014 | B2 |
9008784 | Chan et al. | Apr 2015 | B2 |
9050086 | Belson et al. | Jun 2015 | B2 |
9089328 | Belson et al. | Jul 2015 | B2 |
9179914 | Belson et al. | Nov 2015 | B2 |
9248049 | Gurtner | Feb 2016 | B2 |
9271858 | Ben-Meir et al. | Mar 2016 | B2 |
9474529 | Belson et al. | Oct 2016 | B2 |
9554799 | Belson et al. | Jan 2017 | B2 |
9554800 | Belson et al. | Jan 2017 | B2 |
9561034 | Belson et al. | Feb 2017 | B2 |
9642621 | Belson et al. | May 2017 | B2 |
9642622 | Belson et al. | May 2017 | B2 |
10010710 | Belson et al. | Jul 2018 | B2 |
20020082668 | Ingman | Jun 2002 | A1 |
20020099315 | Lebner | Jul 2002 | A1 |
20030065294 | Pickup | Apr 2003 | A1 |
20030108352 | Hellman | Jun 2003 | A1 |
20030120198 | Barkell et al. | Jun 2003 | A1 |
20030163160 | O'Malley et al. | Aug 2003 | A1 |
20030220596 | Dunshee | Nov 2003 | A1 |
20040072964 | Udding et al. | Apr 2004 | A1 |
20040106904 | Gonnelli et al. | Jun 2004 | A1 |
20040204740 | Weiser | Oct 2004 | A1 |
20040210176 | Diana | Oct 2004 | A1 |
20040260234 | Srinivasan et al. | Dec 2004 | A1 |
20050020956 | Lebner | Jan 2005 | A1 |
20050020957 | Lebner | Jan 2005 | A1 |
20050070956 | Rousseau | Mar 2005 | A1 |
20050080453 | Lebner et al. | Apr 2005 | A1 |
20050085757 | Santanello | Apr 2005 | A1 |
20050153090 | Marchitto et al. | Jul 2005 | A1 |
20050234485 | Seegert et al. | Oct 2005 | A1 |
20050277959 | Cosgrove et al. | Dec 2005 | A1 |
20050284801 | Tacklind | Dec 2005 | A1 |
20060030886 | Clark | Feb 2006 | A1 |
20060122522 | Chavan | Jun 2006 | A1 |
20060200198 | Riskin et al. | Sep 2006 | A1 |
20060259033 | Nesbitt | Nov 2006 | A1 |
20070026078 | Almarsson et al. | Feb 2007 | A1 |
20070038247 | Lebner et al. | Feb 2007 | A1 |
20070078366 | Haggstrom et al. | Apr 2007 | A1 |
20070088339 | Luchetti et al. | Apr 2007 | A1 |
20070106277 | Hood | May 2007 | A1 |
20070141130 | Villanueva et al. | Jun 2007 | A1 |
20070179419 | Simpson | Aug 2007 | A1 |
20070185432 | Etheredge, III | Aug 2007 | A1 |
20070260278 | Wheeler et al. | Nov 2007 | A1 |
20080033334 | Gurtner et al. | Feb 2008 | A1 |
20080069855 | Bonutti | Mar 2008 | A1 |
20080081951 | Frasier et al. | Apr 2008 | A1 |
20080103550 | Wenzel et al. | May 2008 | A1 |
20080114396 | Cory et al. | May 2008 | A1 |
20080147115 | O'Malley et al. | Jun 2008 | A1 |
20080161731 | Woods et al. | Jul 2008 | A1 |
20080228219 | Weiser | Sep 2008 | A1 |
20080287864 | Rosenberg | Nov 2008 | A1 |
20090036922 | Riskin et al. | Feb 2009 | A1 |
20090062531 | Kanda | Mar 2009 | A1 |
20090099496 | Heegaard et al. | Apr 2009 | A1 |
20090149869 | Lhun | Jun 2009 | A1 |
20090158131 | Choi et al. | Jun 2009 | A1 |
20090162531 | Nesbitt | Jun 2009 | A1 |
20090177225 | Nunez et al. | Jul 2009 | A1 |
20090177227 | Warren | Jul 2009 | A1 |
20090264709 | Blurton et al. | Oct 2009 | A1 |
20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
20090299257 | Long et al. | Dec 2009 | A1 |
20090299303 | Seegert | Dec 2009 | A1 |
20100036209 | Ferren et al. | Feb 2010 | A1 |
20100100022 | Greener et al. | Apr 2010 | A1 |
20100121286 | Locke et al. | May 2010 | A1 |
20100228287 | Jeekel et al. | Sep 2010 | A1 |
20100280545 | Fridman | Nov 2010 | A1 |
20110077667 | Singhatat et al. | Mar 2011 | A1 |
20110106026 | Wu | May 2011 | A1 |
20110118698 | Eckhoff et al. | May 2011 | A1 |
20110144470 | Mazar et al. | Jun 2011 | A1 |
20120016410 | Belson et al. | Jan 2012 | A1 |
20120029266 | Holmes et al. | Feb 2012 | A1 |
20120046691 | Belson et al. | Feb 2012 | A1 |
20120095502 | Bargon et al. | Apr 2012 | A1 |
20120116279 | Munro et al. | May 2012 | A1 |
20120116485 | Burgmann | May 2012 | A1 |
20120203273 | Riskin et al. | Aug 2012 | A1 |
20120221044 | Archibald et al. | Aug 2012 | A1 |
20120226214 | Gurtner et al. | Sep 2012 | A1 |
20120232587 | Burke et al. | Sep 2012 | A1 |
20130066365 | Belson et al. | Mar 2013 | A1 |
20130072969 | Zhang | Mar 2013 | A1 |
20130108352 | Ruiz, Sr. et al. | May 2013 | A1 |
20130178897 | Wu et al. | Jul 2013 | A1 |
20130267928 | Imran et al. | Oct 2013 | A1 |
20130281885 | Rowbottom et al. | Oct 2013 | A1 |
20130281981 | Shamir | Oct 2013 | A1 |
20130282049 | Peterson et al. | Oct 2013 | A1 |
20130296930 | Belson et al. | Nov 2013 | A1 |
20130331757 | Belson | Dec 2013 | A1 |
20140074156 | Belson et al. | Mar 2014 | A1 |
20140171849 | Fischell et al. | Jun 2014 | A1 |
20140222070 | Belson et al. | Aug 2014 | A1 |
20140228712 | Elliott et al. | Aug 2014 | A1 |
20140278229 | Hong et al. | Sep 2014 | A1 |
20140316323 | Kanevsky | Oct 2014 | A1 |
20150045700 | Cavanagh et al. | Feb 2015 | A1 |
20150105423 | Haudenschild et al. | Apr 2015 | A1 |
20150148653 | Fleig et al. | May 2015 | A1 |
20150209563 | Amir | Jul 2015 | A1 |
20150216527 | Belson et al. | Aug 2015 | A1 |
20150309535 | Connor et al. | Oct 2015 | A1 |
20150313593 | Patenaude et al. | Nov 2015 | A1 |
20150351690 | Toth et al. | Dec 2015 | A1 |
20160007909 | Singh et al. | Jan 2016 | A1 |
20160058998 | Skiba | Mar 2016 | A1 |
20160095597 | Belson et al. | Apr 2016 | A1 |
20160106931 | Belson et al. | Apr 2016 | A1 |
20160114146 | Belson et al. | Apr 2016 | A1 |
20160202755 | Connor | Jul 2016 | A1 |
20160206311 | Belson et al. | Jul 2016 | A1 |
20160206312 | Belson et al. | Jul 2016 | A1 |
20160206313 | Belson et al. | Jul 2016 | A1 |
20160213924 | Coleman et al. | Jul 2016 | A1 |
20160220175 | Tam et al. | Aug 2016 | A1 |
20160220252 | Belson et al. | Aug 2016 | A1 |
20160242646 | Obma | Aug 2016 | A1 |
20160249924 | Belson et al. | Sep 2016 | A1 |
20160296149 | Polsky et al. | Oct 2016 | A1 |
20160302721 | Wiedenhoefer et al. | Oct 2016 | A1 |
20160310140 | Belson et al. | Oct 2016 | A1 |
20170035422 | Belson et al. | Feb 2017 | A1 |
20170042541 | Belson et al. | Feb 2017 | A1 |
20170143341 | Belson et al. | May 2017 | A1 |
20170156664 | Belson et al. | Jun 2017 | A1 |
20190060128 | Belson | Feb 2019 | A1 |
Number | Date | Country |
---|---|---|
1126430 | Jul 1996 | CN |
1442119 | Sep 2003 | CN |
1524507 | Sep 2004 | CN |
1234327 | Jan 2006 | CN |
101563113 | Oct 2009 | CN |
101801456 | Aug 2010 | CN |
101938944 | Jan 2011 | CN |
202537562 | Nov 2012 | CN |
102946812 | Feb 2013 | CN |
104755033 | Jul 2015 | CN |
104825200 | Aug 2015 | CN |
1600108 | Nov 2005 | EP |
1401877 | Aug 1975 | GB |
S4868094 | Sep 1973 | JP |
S5094788 | Jul 1975 | JP |
S5223497 | Jun 1977 | JP |
S62243557 | Oct 1987 | JP |
S62243557 | Oct 1987 | JP |
H07502913 | Mar 1995 | JP |
2001149485 | Jun 2001 | JP |
2005512678 | May 2005 | JP |
2005532134 | Oct 2005 | JP |
2010504835 | Feb 2010 | JP |
2013515417 | May 2013 | JP |
2013538603 | Oct 2013 | JP |
WO-8401805 | May 1984 | WO |
WO-9629013 | Sep 1996 | WO |
WO-03053296 | Jul 2003 | WO |
WO-2006124671 | Nov 2006 | WO |
WO-2007004603 | Jan 2007 | WO |
WO-2007044647 | Apr 2007 | WO |
WO-2008019051 | Feb 2008 | WO |
WO-2008060532 | May 2008 | WO |
WO-2009066116 | May 2009 | WO |
WO-2011019859 | Feb 2011 | WO |
WO-2011019859 | Apr 2011 | WO |
WO-2011043786 | Apr 2011 | WO |
WO-2011139912 | Nov 2011 | WO |
WO-2011159623 | Dec 2011 | WO |
WO-2013067024 | May 2013 | WO |
WO-2014066879 | May 2014 | WO |
WO-2014070922 | May 2014 | WO |
WO-2015012887 | Jan 2015 | WO |
WO-2015103556 | Jul 2015 | WO |
WO-2015168165 | Nov 2015 | WO |
WO-2017027075 | Feb 2017 | WO |
WO-2017044120 | Mar 2017 | WO |
WO-2017181059 | Oct 2017 | WO |
WO-2017184825 | Oct 2017 | WO |
WO-2018081795 | May 2018 | WO |
Entry |
---|
Co-pending U.S. Appl. No. 15/337,768, filed Oct. 28, 2016. |
Co-pending U.S. Appl. No. 15/369,239, filed Dec. 5, 2016. |
Notice of allowance dated Sep. 30, 2016 for U.S. Appl. No. 15/130,149. |
Notice of allowance dated Oct. 5, 2016 for U.S. Appl. No. 15/096,083. |
Notice of allowance dated Oct. 14, 2016 for U.S. Appl. No. 15/081,550. |
Office action dated Feb. 1, 2017 for U.S. Appl. No. 15/130,764. |
Office action dated Nov. 17, 2016 for U.S. Appl. No. 15/081,595. |
Office action dated Dec. 1, 2016 for U.S. Appl. No. 13/665,160. |
Co-pending U.S Appl. No. 15/130,149, filed Apr. 15, 2016. |
Co-pending U.S Appl. No. 15/130,764, filed Apr. 15, 2016. |
European search report and opinion dated Jan. 7, 2014 for EP Application No. 11778067.6. |
European search report and opinion dated Jan. 7, 2014 for EP Application No. 11796253.0. |
European search report and opinion dated Apr. 29, 2015 for EP Application No. 10822334.8. |
European search report and opinion dated Jul. 12, 2016 for EP Application No. 13851258. |
European search report and written opinion dated Aug. 12, 2015 for EP Application No. 12844746.3. |
Hasson, et al. A new sutureless technique for skin closure. Arch Surg. Jan. 1976;111(1):83-4. |
International search report and written opinion dated Jan. 12, 2016 for PCT Application No. US2015/049671. |
International search report and written opinion dated Feb. 6, 2014 for PCT/US2013/067563. |
International search report and written opinion dated Mar. 19, 2013 for PCT/US2012/062820. |
International search report and written opinion dated Apr. 29, 2015 for PCT/US2015/010188. |
International search report and written opinion dated Jul. 29, 2011 for PCT/US2011/034649. |
International search report and written opinion dated Jul. 30, 2010 for PCT/US2010/000430. |
International search report and written opinion dated Sep. 10, 2014 for PCT/US2014/016587. |
International search report and written opinion dated Sep. 30, 2015 for PCT Application No. US2015/28066. |
International search report and written opinion dated Oct. 21, 2011 for PCT Application No. US11/40213. |
K984204, 510(k) Premarket Notification Summary, Silverlon™ Direct Pressure Wound Closure Strip, May 19, 2007. |
Merriam-Webster Dictionary. Definition of “lateral”. Http://www.merriam-webster.com/dictionary/lateral. Accessed on May 5, 2016. |
Notice of allowance dated Jan. 17, 2013 for U.S. Appl. No. 13/096,602. |
Notice of allowance dated Feb. 10, 2015 for U.S. Appl. No. 14/180,524. |
Notice of allowance dated Jun. 21, 2016 for U.S. Appl. No. 15/081,526. |
Notice of allowance dated Sep. 17, 2012 for U.S. Appl. No. 13/286,378. |
Notice of allowance dated Sep. 20, 2012 for U.S. Appl. No. 13/286,757. |
Notice of allowance dated Sep. 22, 2015 for U.S. Appl. No. 13/414,176. |
Notice of allowance dated Dec. 19, 2014 for U.S. Appl. No. 14/180,564. |
Office action dated Feb. 26, 2015 for U.S. Appl. No. 13/414,176. |
Office action dated Mar. 4, 2016 for U.S. Appl. No. 13/874,046. |
Office action dated Mar. 21, 2012 for U.S. Appl. No. 13/286,378. |
Office action dated Mar. 21, 2014 for U.S. Appl. No. 13/414,176. |
Office action dated Mar. 22, 2012 for U.S. Appl. No. 13/286,757. |
“Office action dated Apr. 7, 2015 for U.S. Appl. No. 13/685,909.”. |
Office action dated May 2, 2012 for U.S. Appl. No. 13/096,602. |
Office action dated May 3, 2016 for U.S. Appl. No. 13/665,160. |
Office action dated May 11, 2016 for U.S. Appl. No. 15/081,595. |
Office action dated May 12, 2016 for U.S. Appl. No. 15/081,550. |
Office action dated May 26, 2016 for U.S. Appl. No. 15/081,526. |
Office action dated May 31, 2016 for U.S. Appl. No. 15/096,083. |
Office action dated Jun. 5, 2015 for U.S. Appl. No. 13/874,046. |
Office action dated Jun. 17, 2014 for U.S. Appl. No. 13/414,176. |
Office action dated Jun. 17, 2016 for U.S. Appl. No. 15/130,149. |
Office action dated Jul. 20, 2016 for U.S. Appl. No. 15/130,764. |
Office action dated Jul. 23, 2012 for U.S. Appl. No. 13/286,378. |
Office action dated Jul. 23, 2012 for U.S. Appl. No. 13/286,757. |
Office action dated Aug. 18, 2014 for U.S. Appl. No. 14/180,564. |
Office action dated Aug. 28, 2014 for U.S. Appl. No. 14/180,524. |
Office action dated Sep. 19, 2014 for U.S. Appl. No. 13/685,909. |
Office action dated Oct. 14, 2015 for U.S. Appl. No. 13/685,909. |
Office action dated Oct. 23, 2015 for U.S. Appl. No. 13/665,160. |
Office action dated Nov. 19, 2012 for U.S. Appl. No. 13/096,602. |
Office action dated Dec. 29, 2014 for U.S. Appl. No. 13/685,909. |
Zip® Surgical Skin Closure. Fast, non-invasive alternative to staples, sutures and glue. Accessed Aug. 17, 2016. http://www.ziplinemedical.com/products/zip-surgical-skin-closure/. |
dictionary.com definition of fixed, accessed on Sep. 13, 2017, http://www.dictionary.com/browse/fixed. |
European search report and opinion dated Feb. 17, 2017 for EP Application No. 140829202. |
European search report with written opinion dated Jul. 12, 2016 for EP13851258. |
Extended European search report and opinion dated Jul. 27, 2017 for EP Application No. 14889182. |
International search report with written opinion dated Jul. 14, 2017 for PCT/US2017/027695. |
International search report with written opinion dated Jul. 18, 2017 for PCT/US2017/028537. |
International search report with written opinion dated Aug. 30, 2016 for PCT/US2016/028297. |
Merriam-webster definition of integral, accessed on Sep. 13, 2017, https://www.merriam-webster.com/dictionary/integral. |
Notice of allowance dated Feb. 21, 2017 for U.S. Appl. No. 14/625,366. |
Notice of allowance dated Feb. 23, 2016 for U.S. Appl. No. 15/081,595. |
Notice of allowance dated Dec. 19, 2016 for U.S. Appl. No. 15/130,149. |
Office action dated Jun. 1, 2017 for U.S. Appl. No. 15/442,382. |
Office action dated Jun. 2, 2017 for U.S. Appl. No. 13/665,160. |
Office action dated Jul. 27, 2017 for U.S. Appl. No. 14/851,059. |
Office action dated Aug. 24, 2017 for U.S. Appl. No. 14/958,803. |
Office Action dated Sep. 22, 2017 for U.S. Appl. No. 13/665,160. |
Office Action dated Sep. 26, 2017 for U.S. Appl. No. 13/685,909. |
Office Action dated Oct. 5, 2017 for U.S. Appl. No. 14/958,818. |
Office Action dated Nov. 22, 2017 for U.S. Appl. No. 15/130,764. |
Office Action dated Nov. 28, 2017 for U.S. Appl. No. 15/442,382. |
PCT/US2017/059286 International Search Report and Written Opinion dated Mar. 6, 2018. |
U.S. Appl. No. 14/851,059 Notice of Allowance dated Mar. 14, 2018. |
International search report and written opinion dated Aug. 30, 2016 for PCT/US2016/028297. |
“Notice of Allowance dated Jun. 15, 2018 for U.S. Appl. No. 13/665,160.”. |
“Notice of Allowance dated Jun. 20, 2018 for U.S. Appl. No. 15/130,764.”. |
“Notice of Allowance mailed Aug. 9, 2018 for U.S. Appl. No. 14/851,059.”. |
Thakral; et al., “Electrical stimulation to accelerate wound healing”, CoAction, 2013, 4: 22061, 1-9. |
“U.S. Appl. No. 14/958,803 Notice of Allowance dated Apr. 4, 2018”. |
U.S. Appl. No. 14/958,803 Notice of Allowance dated May 11, 2018. |
U.S. Appl. No. 13/096,602, filed Apr. 28, 2011. |
U.S. Appl. No. 13/286,378, filed Nov. 1, 2011. |
U.S. Appn. No. 13/286,757, filed Nov. 1, 2011. |
U.S. Appn. No. 13/665,160, filed Oct. 31, 2012. |
U.S. Appl. No. 13/685,909, filed Nov. 27, 2012. |
U.S. Appl. No. 13/874,046, filed Apr. 30, 2013. |
U.S. Appl. No. 14/180,524, filed Feb. 14, 2014. |
U.S. Appl. No. 14/180,564, filed Feb. 14, 2014. |
U.S. Appl. No. 14/625,366, filed Feb. 18, 2015. |
“U.S. Appl. No. 13/685,909 Office Action dated May 1, 2018”. |
“Office action dated Feb. 25, 2019 for U.S. Appl. No. 15/369,293.”. |
“Office action dated Mar. 26, 2019 for U.S. Appl. No. 16/132,736”. |
“Office action dated Nov. 2, 2018 for U.S. Appl. No. 15/442,382.”. |
Ann; Davis et al., “Effect of Surgical Incision Closure Device on Skin Perfusion Following Total Ankle Arthroplasty”, UFHealth, 2017, Poster. |
Bauback; Safa et al., “In Vivo Efficacy Study Showing Comparative Advantage of Bacterial Infection Prevention with Zip-type Skin Closure Device vs. Subcuticular Sutures”, Cureus, Aug. 4, 2018, 3102, 1-11. |
Cody; C. Wyles et al., “Running Subcuticular Closure Enables the Most Robust Perfusion After TKA: A Randomized Clinical Trial”, Clinical Orthopaedics and Related Research, Springer, Mar. 3, 2015, 1-10. |
Kemal; Levi et al., “Mechanics of Wound Closure: Emerging Tape-Based Wound Closure Technology vs. Traditional Methods”, Cureus, Oct. 12, 2016, 827, 1-5. |
Number | Date | Country | |
---|---|---|---|
20160310140 A1 | Oct 2016 | US |
Number | Date | Country | |
---|---|---|---|
61964477 | Jan 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2015/010188 | Jan 2015 | US |
Child | 15201088 | US |